Weight loss unrelated to decrease in calorie intake after a single dose of a bispecific antibody to FGFR1/Klothoβ in obese subjects

Publication Authors:

Arora, P.S.; Wong, C; Baruch, A; Chinn, L; Vaze, A; Sonoda, J; Gelzleichter, T; Chen, S; Lewin-Koh, N; Morrow, L; Boismenu, R

Poster presented at 53rd European Association for the Study of Diabetes (EASD) Annual Meeting, Lisbon, Portugal, September 2017.

About this Poster:

BFKB8488A is a humanized, effector-less, bispecific antibody designed to activate the receptor for fibroblast growth factor 21 (FGF21) in adipose tissue, the FGFR1/Klothoß complex. Preclinical studies demonstrated that BFKB8488A largely recapitulates the metabolic actions of recombinant FGF21 in rodents and non-human primates. This Phase 1, first-in-human study was performed with obese but otherwise healthy subjects. The primary objectives were safety, tolerability, and pharmacokinetics. Additionally, insulin, glucose, lipids, and other metabolic markers were measured.

no alt text set
no